Article - 10/05/2008 Straight questions and answers The 14th Biotech Finance Forum offered selected biotechnology and medical technology companies from all over Europe the opportunity of an exclusive meeting with internationally operative investors from the venture capital VC scene. https://www.gesundheitsindustrie-bw.de/en/article/news/straight-questions-and-answers
Press release - 07/05/2008 ChemCon – and how an ideal niche was found and occupied At first sight the business idea seems somehow strange Who would deliberately choose to develop and produce pharmaceutical substances that are hardly required and if so only in small quantities. Dr. Raphael Vogler and Dr. Peter Gockel the founders and owners of Freiburg-based ChemCon GmbH have done exactly that - and found an ideal niche for their company. Even the largest companies of the industry are benefiting from ChemCons know-how and…https://www.gesundheitsindustrie-bw.de/en/article/press-release/chemcon-and-how-an-ideal-niche-was-found-and-occupied
Article - 03/05/2008 Immatics started second proof-of-concept study Immatics biotechnologies GmbH announced the start of a Phase III trial of its IMA910 cancer vaccine in patients with advanced colorectal cancer. The study will enroll about 70 patients in 8 European countries. The vaccine is developed to slow or halt tumor progression.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-started-second-proof-of-concept-study
Article - 01/05/2008 Peter Öhlschläger - New strategies for the treatment of cancer Professor Peter Öhlschläger established his major scientific interests very early on. During his degree thesis at the German Cancer Research Centre DKFZ in Heidelberg the immunologist succeeded in combining his two major interests namely virology and cancer. Öhlschläger is now junior professor at the University of Constance and mainly deals with the development of therapeutic cancer vaccines. https://www.gesundheitsindustrie-bw.de/en/article/news/peter-hlschlaeger-new-strategies-for-the-treatment-of-cancer
Article - 28/04/2008 A milestone in the treatment of leukaemia Blood cancer experts in the team of Professor Peter Dreger Head of the Section of Allogeneic Stem Cell Transplantation at the University Hospital of Heidelberg have achieved a major success in the treatment of leukaemia. For the 500th time the physicians from the Department of Haematology Oncology and Rheumatology transferred blood stem cells from a healthy donor to a patient suffering from leukaemia or lymphoma.https://www.gesundheitsindustrie-bw.de/en/article/press-release/a-milestone-in-the-treatment-of-leukaemia
Article - 21/04/2008 Human blood system in mice Scientists from Mannheim Heidelberg an Freiburg working together in the cooperative research area Vascular Biology have developed a method that can be used to create a human vascular system in mice which stays functional even after several months.https://www.gesundheitsindustrie-bw.de/en/article/news/human-blood-system-in-mice
Article - 20/04/2008 varionostic develops test systems for tumour markers The Ulm-based company varionostic GmbH has received a research grant from the German Ministry of Economics and Technology. Details on the level of the grant were not disclosed. The company will research tumour markers and develop detection systems for DNA methylations.https://www.gesundheitsindustrie-bw.de/en/article/news/varionostic-develops-test-systems-for-tumour-markers
Article - 16/04/2008 Roland Schuele - "Research cannot be predicted" Professor Roland Schuele from the University Womens Hospital in Freiburg originally studied biochemistry. Nowadays Schuele is researching the development of prostate cancer. During his scientific career he has learnt that research cannot be steered in a particular direction. It develops and we follow it said Schuele who has been able to gain astonishing insights into the molecular processes in tumour cells.https://www.gesundheitsindustrie-bw.de/en/article/news/roland-schuele-research-cannot-be-predicted
Press release - 16/04/2008 Effective Cancer Immune Therapy Through Order in the Blood Vessels Researchers at the German Cancer Research Center have discovered a key molecule that is responsible for the immature structure of blood vessels in malignant tumors. If this molecule is switched off in mice vessels normalize so that immune cells are better able to get to the tumor tissue.https://www.gesundheitsindustrie-bw.de/en/article/press-release/effective-cancer-immune-therapy-through-order-in-the-blood-vessels
Article - 13/04/2008 Selective internal radiotherapy Since early 2008 the Institute of Clinical Radiology and Nuclear Medicine at Mannheim University Hospital has been offering a new therapy for the treatment of liver cancers selective internal radiotherapy SIRT.https://www.gesundheitsindustrie-bw.de/en/article/news/selective-internal-radiotherapy
Article - 13/04/2008 Scientists discover a genetic dependence to nicotine Scientists have shown that a particular variant of a receptor gene impacts smoking behaviour and hence confers a 30 increase in risk of lung cancer and a 20 increase in risk of peripheral artery disease PAD.https://www.gesundheitsindustrie-bw.de/en/article/press-release/scientists-discover-a-genetic-dependence-to-nicotine
Article - 05/04/2008 Successful cooperation between science and industry (II) In the second article in the series on the platforms successful cooperations BioValley presents an encouraging approach for improving the quality of life of severely ill cancer patients and the successful establishment of an industrial biochip platform. https://www.gesundheitsindustrie-bw.de/en/article/news/successful-cooperation-between-science-and-industry-ii
Article - 31/03/2008 First biosimilar from Ulm close to approval ratiopharm Germanys second largest generics producer received a positive assessment from the EU regulatory body EMEA in London for the first filgrastim biosimilar. The company expects to receive marketing authorisation for its first biosimilar by mid to end April.https://www.gesundheitsindustrie-bw.de/en/article/news/first-biosimilar-from-ulm-close-to-approval
Article - 31/03/2008 "Nanomedicine will be able to combat incurable diseases" The first European Conference for Clinical Nanomedicine is to be held soon in Basel. BIOPRO has therefore discussed this promising area of application with Beat Löffler and Dr. Patrick Hunziker the founders of the European Foundation for Clinical Nanomedicine.https://www.gesundheitsindustrie-bw.de/en/article/news/nanomedicine-will-be-able-to-combat-incurable-diseases
Article - 25/03/2008 A real milestone Somatic cell nuclear transfer or reprogramming of somatic cells into a near embryonic state - it is now expected that stem cell experts rate their findings in the field of stem cell research. What can be called a breakthrough? What is the scientific value?https://www.gesundheitsindustrie-bw.de/en/article/news/a-real-milestone
Article - 16/03/2008 New indication for lead compound of Apogenix Isolated tumour cells use to invade healthy brain tissue during the development and growth of glioblastoma multiforme GBM. This mechanism involves the CD95CD95L death system. These results supports the therapeutic potential of Apogenix APG101 for the treatment of glioblastomas.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-indication-for-lead-compound-of-apogenix
Article - 15/03/2008 Two Cluster of the Rhine-Neckar Metropolitan successful Of twelve applications which qualified for the decisive final round of the top cluster competion two are from the Rhine-Neckar metropolitan area the Forum Organic Electronics cluster and the Cell-Based Molecular Medicine biotechnology cluster.https://www.gesundheitsindustrie-bw.de/en/article/news/two-cluster-of-the-rhine-neckar-metropolitan-successful
Article - 11/03/2008 Nils Johnsson delivers initial insights Nils Johnssons work focuses on communication research involving living objects. The 48-year-old biochemist is investigating how proteins manage the complicated process of cytokinesis the division of the cell plasma. Thanks to a specific method Johnsson is able to detect when proteins are interacting with each other.https://www.gesundheitsindustrie-bw.de/en/article/news/nils-johnsson-delivers-initial-insights
Article - 09/03/2008 Successful attack on resistant tumour cells In laboratory experiments Dr. Anja Apel from the University Hospital in Heidelberg proved that cancer cells that are resistant to radiation therapy can be made to become susceptible to this kind of treatment again by blocking the cells own recycling system.https://www.gesundheitsindustrie-bw.de/en/article/press-release/successful-attack-on-resistant-tumour-cells
Article - 07/03/2008 Hans-Ulrich Kauczor - expert in diagnostic radiology Since the 1st March 2008 the Department of Diagnostic Radiology at the University Hospital in Heidelberg has a new medical director Professor Dr. Hans-Ulrich Kauczor 45 succeeds Professor Dr. Günter Kauffmann.https://www.gesundheitsindustrie-bw.de/en/article/press-release/hans-ulrich-kauczor-expert-in-diagnostic-radiology
Article - 02/03/2008 Miniature device offers great opportunities The Dietmar Hopp Foundation has donated one million euro for a new small-animal tomograph at the University Hospital in Heidelberg. The new system is suitable for small animals such as rats and mice and can be used to investigate diseases and therapies.https://www.gesundheitsindustrie-bw.de/en/article/news/miniature-device-offers-great-opportunities
Article - 28/02/2008 Gilbert Gorr - a great fan of the moss Physcomitrella patens Dr. Gilbert Gorr has been fascinated by the moss Physcomitrella patens for many years in fact it occupies a great deal of his waking moments. The enthusiasm with which the CSO of greenovation Biotech GmbH talks about the key object of his work is both intoxicating and contagious. The latest discovery The moss produces a therapeutic antibody that is far more effective than its predecessors created in animal cell cultures.https://www.gesundheitsindustrie-bw.de/en/article/news/gilbert-gorr-a-great-fan-of-the-moss-physcomitrella-patens
Article - 16/02/2008 Haemochromatosis is a disease of the liver Haemochromatosis is not as has been previously assumed a disease of the small intestine but a disease of the liver. Scientists from Heidelberg have shown in the animal model that the disease is caused by a mutated gene influencing hepcidin production.https://www.gesundheitsindustrie-bw.de/en/article/news/haemochromatosis-is-a-disease-of-the-liver
Article - 16/02/2008 New test for the early diagnosis of cervical cancer mtm laboratories has launched the Cervatec assay for the early diagnosis of cervical cancer. The Cervatec assay will initially be commercialized as an adjunct to the Pap test for the screening of women aged 35 and younger.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-test-for-the-early-diagnosis-of-cervical-cancer
Article - 10/02/2008 4th Biomarker Workshop at the NMI in Reutlingen: another success The Biomarker Workshop held at the NMI in late January has become a fixed date for a growing number of proteomics researchers. With an attendance of 130 this years workshop exceeded all previous ones. Those who were keen to find out more about the latest trends and findings were presented with a successful mix of basic and applied research information.https://www.gesundheitsindustrie-bw.de/en/article/news/4th-biomarker-workshop-at-the-nmi-in-reutlingen-another-success